Braveheart Bio (BRVE) presented its dual therapeutic strategy for hypertrophic cardiomyopathy (HCM) at the Cantor Fitzgerald Global Healthcare Conference, emphasizing progress in Phase II trials and strategic partnerships. The company’s lead candidate, BHB-1893—a cardiac myosin inhibitor—is advancing in two distinct HCM subpopulations: obstructive and non-obstructive forms, each with distinct Phase III programs under development. CEO Travis Murdock, former Biogen executive and founder of HI-Bio, outlined clinical milestones and financial positioning ahead of potential regulatory filings and an IPO expected to fund operations through 2029.
In obstructive HCM, the Phase II open-label dose-ranging study demonstrated rapid efficacy, with over 86% of patients achieving a complete Valsalva gradient response by 28 weeks. Early gradient reductions were observed as early as one week, and a simplified titration regimen for Phase III (LIONHEART-HCM) aims to streamline monitoring. The interim analysis, planned for the second half of 2025, will include 60 patients (40 on drug, 20 placebo) assessed at 12 weeks, with a focus on gradient reduction, safety, and pharmacokinetics. The program also incorporates Asian patient cohorts to support regional translatability.
For non-obstructive HCM, Braveheart’s collaboration with Hengrui Pharmaceuticals revealed encouraging Phase II results in a 12-week placebo-controlled trial. The high-dose arm showed a 5.5-point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ), with over 50% of patients achieving a 20-point KCCQ improvement. Biomarker improvements—including NT-proBNP and troponin—alongside echocardiographic metrics (normalization of septal and lateral e’ prime values) and reductions in left atrial volume index and wall thickness were also noted. The Phase III program (NobleHeart) is set for a 36-week endpoint with dual primary endpoints of KCCQ and peak VO₂, aiming to be the second-to-market treatment for non-obstructive HCM.
Braveheart’s financial health reflects a cautious but robust posture. With a current ratio of 8.11, the company’s liquid assets substantially exceed short-term obligations, though it remains unprofitable, reporting a negative diluted EPS of $11.53 over the past year. The stock has seen a 10% return over the past week, closing at $27.02. The company’s IPO raised capital to sustain operations through 2029, while strategic partnerships—including with Hengrui—are viewed as critical for de-risking regulatory pathways. Regulatory timelines include Phase III data from Hengrui in the first half of 2025 and Braveheart’s own interim analysis for obstructive HCM in the second half of 2025, with additional open-label extension data expected by late 2024.
Braveheart’s dual HCM strategy positions it to compete with established therapies, including those in the ODYSSEY and ACACIA-HCM trials, while leveraging its clinical and financial flexibility. The company’s focus on regional inclusivity and simplified clinical protocols underscores its commitment to addressing unmet needs in a rare but critical cardiovascular disease space.
